echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hisun Pharmaceutical's tigecycline for injection passed the consistency evaluation

    Hisun Pharmaceutical's tigecycline for injection passed the consistency evaluation

    • Last Update: 2021-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 31, Hisun Pharmaceutical issued an announcement stating that it had recently received the "Drug Supplementary Application Approval Notice" for tigecycline for injection approved and issued by the State Food and Drug Administration.


    Tigecycline for injection is mainly suitable for the treatment of infections caused by sensitive strains of specific bacteria in patients over 18 years of age under the following conditions: complicated intra-abdominal infections, complicated skin and skin soft tissue infections, and community-acquired bacterial pneumonia.


    According to statistics, the global sales of tigecycline for injection in 2019 are approximately US$358,484,100, of which China’s sales are approximately US$177,563,900; the global sales in 2020 are approximately US$343.


    Hisun Pharmaceutical's sales revenue of tigecycline for injection in 2020 was 205,995,900 yuan.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.